Aquestive Therapeutics, Inc. · NASDAQ:AQST
Aquestive Therapeutics — Q2 2023 Earnings Presentation
11 slides from Aquestive Therapeutics's earnings presentation, Aug 7, 2023
Slide 1: Q2 2023 Supplemental Earnings
WU | AJOS OUCAPY €zoz ‘Zysn6ny 2La}e\ je}UsWe|ddns sbulwez €Z0Z ZO by >
Slide 2: Forward-looking statements
-ou| ‘soynadesey anysenby Jo Auadoid €Z0Z © sroumo aanoadsas s1oup jo Auodosd ayp ze ujas0y paouaigjor S[PUIOPEN ParoIS!FO4 L9YPO0 [TY “601-LSOY ‘AepIpuRd ronpoad axp Jo peaoudde Ys Uo pouontpuod st oureu eaoudde eur “yard ay) £4 paaoudde sjjeuorpuos uadq seq, wuy<YdeUY,, 601-LSOV 40} SUIeU apeN aYL
Slide 3: Key messages: Libervant and Anaphylm updates
uojeoidde dnoib pjo-seak Z| panoidde Ajaniyeju9} 10} 7707 UE} JOUOOS Ss8d9e JOyJeEW “S*F) JO} WG OU} YIM eHeBus oO} enuUOD = dnos6 a6e pjo-se9h aay 0} -om) ul Spaau JoWUN JUaed Sseuppe IM ‘JeyseW Ul UBYM ‘JUeAIOIT JEU} BJedionuy — sujuoW omy Ajayewuixoidde ulyym UoHeo!|dde 2 84} UO WG-4 ey} Woy Jeay
Slide 4: Q2 2023 highlights
€Z0Z LO woy %Ev JO eseeioul — sesop W6' Zr painjoejnuey| ves jo souejeq yseo Bulpuy veg JO JuawAed jediould yep peinpeyos pled plo sueak Gg pue Zz usamjaq sjualjed Jo} VON jueMeq!] peyiwgns Anne salpnys jojid wjAydeuy woy s}iNsel aalisod poyioday AVIN ZO Ul UOI}NDExy JUs}SISUOD > ynsme| aAeAUap Japj
Slide 5: Ending cash in US millions
suomi GSN Ul seunBy iy €70Z TOM =EZOTLOM 2z20Z POM 72Z07EDm 72z0¢ ZOe yseo Buipug 0 S OL : SL 98h aoe 0z Sz og sayeny Aq yseo Bulpuy UOHISOd YyseO INC ebeueyy 0} Bulnuguog 9
Slide 6: Ending debt in US millions
suomi GSN ul sesnBy IY €20Z pO EZOTEDM EZOTZOM EZOTLOM ZZ0z7POm yqeq Bulpuy o6e vey Gis Jayena Aq }qeq pejseoe04 D OIIGNd & SB OU }SJI4 OU} JO} WOH$ MOjeg UONISOd }Geq y
Slide 7: Manufacturing Operations
4 WU | A|OS OUCAPY/ uoneisdg¢g BbulinjoOejnuep by >
Slide 8: Manufacturing volumes and cash flow
€20Z LO 2202 vO e202 €D Z202 ZO 7202 LO L202 vO }20Z €D L20¢ ZO (SNOITIIW) SWNIOA @WI1ISNYVHd moj4 yseg ) pue suole}oedxy joa 0} eNUUOD SUONeJedG BuLNjoeynuew 9 >
Slide 9: Outlook 2023
6 WU | OS acne c 001}NO €2z0 y
Slide 10: 2023 outlook: revenues and non-GAAP adjusted EBITDA loss
OL 77$ 0} CL$ Ajoyetuixoidde jo ssoj YGLIGA peisnipe dyVO-UON - WW gr$ 0} pr} AjoyewIxoidde jo sonusAsi jejo]« €z0z 3snBbny jo se yoo)}3no €z0z eouepIny pasiAey — ayepd¢n yoo}3no ¢z0z I>
Slide 11: acne
WU | OS acne A 4UeUL late)
Aquestive Therapeutics — Q2 2023 Earnings Presentation on 6ix